Join the club for FREE to access the whole archive and other member benefits.

Eli Lilly's Alzheimer's drug passed phase 2 trial


Key points from article :

TRAILBLAZER-ALZ Phase 2 study assessed the safety, tolerability and efficacy of donanemab in patients with Alzheimer's disease.

Donanemab, an investigational antibody showed significant slowing of decline in a composite measure of cognition and daily function.

Showed consistent improvements in primary and all prespecified secondary endpoints measuring cognition and function.

"Donanemab is a potential therapy for people living with Alzheimer's disease, the only leading cause of death without a treatment," - Mark Mintun, vice president, Eli Lilly and Company.

Treatment has been shown to rapidly result in high levels of amyloid plaque clearance.

"The positive results of donanemab support its rapid and deep plaque clearance for the potential treatment of Alzheimer's disease," - Daniel Skovronsky, Lilly's chief scientific officer.

Full results of the TRAILBLAZER-ALZ study will be submitted for publication in a peer-reviewed clinical journal.

Clears plaque and slows clinical decline in patients with early-stage Alzheimer's

Mentioned in this article:

Company Representative

Senior Vice President and Chief Scientific Officer, Eli Lilly and Company

Company Representative

Vice-President of Pain and Neurodegeneration, Eli Lilly and Company